HUTCHMED GSK Licensing Deal Boosts Pipeline Prospects
HUTCHMED GSK licensing deal gives $110 million upfront and up to $1.2 billion in milestones, reshaping near-term cash profile and investor positioning.
KEY TAKEAWAYS
- HUTCHMED will receive a $110 million upfront and up to $1.2 billion in milestone payments.
- Upfront is payable at closing and subject to customary conditions including antitrust reviews.
- HUTCHMED will lead a global Phase I expected to start in H2 2026.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
HUTCHMED (China) Limited said in a press release on Sept. 3, 2026, that it signed an exclusive licensing agreement with a GlaxoSmithKline plc (GSK) unit granting the latter rights to develop and commercialize HMPL‑A830 outside Greater China. The deal assigns HUTCHMED to lead a global Phase I trial starting in the second half of 2026, reshaping development responsibilities and potential revenue streams.
Deal Terms and Clinical Development
HUTCHMED Limited, a subsidiary of the Hong Kong-based biopharmaceutical company HUTCHMED (ticker HCM), executed the agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited, a GSK unit. The contract grants GSK exclusive rights to HMPL‑A830 worldwide except for Mainland China, Hong Kong, Macau, and Taiwan, where HUTCHMED retains full development and commercialization rights.
The GSK unit will pay $110 million upfront at closing, which is subject to customary conditions including antitrust regulatory reviews. HUTCHMED may receive up to $1.185 billion in development, regulatory, and commercial milestone payments, bringing the total potential deal value to $1.295 billion. The agreement also includes tiered royalties on GSK’s annual net sales outside Greater China.
HMPL‑A830 is a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) currently in preclinical development. It combines a highly selective, potent KRAS small-molecule inhibitor with an anti-EGFR antibody to target tumors expressing KRAS mutations and EGFR. Clinical development will initially focus on colorectal, pancreatic, and lung cancers, where these mutations are common.
HUTCHMED will lead a two-part global Phase I trial registered as NCT07718581, expected to start in the second half of 2026. After Phase I, GSK will take over subsequent clinical development and commercialization outside the retained Greater China territories. The agreement also grants GSK a right of first negotiation on one earlier-stage ATTC candidate, supporting potential future collaboration as HUTCHMED expands its global oncology portfolio.
Separately, on Aug. 28, 2026, HUTCHMED announced that China’s National Medical Products Administration granted conditional approval for Atled (fantegratinib), adding to its marketed oncology drugs in Greater China.
